InforSense GenSense Achieves GeneChip-compatible™ Status with the Affymetrix GeneChip® Microarray Platform
News Aug 07, 2007
InforSense Ltd. has announced that it has joined the Affymetrix GeneChip-compatible Applications Program, and that its InforSense GenSense solution, has achieved GeneChip-compatible™ status with the Affymetrix GeneChip® microarray platform.
In addition, Affymetrix has become a member of InforSense’s Open Workflow Partner Network (OWPN) joining over 40 other partners in the program.
The integration will enable scientists to analyze and interpret both the Affymetrix Genome-Wide Human SNP 5.0 and SNP 6.0 arrays. Workflows provided with the solution also include access to Affymetrix Power Tools for Loss of Heterozygosity (LOH) and Copy Number Variation (CNV) as well as the Affymetrix calling algorithms, including BRLMM , BRLMM-p and Birdseed.
“We are please to welcome GenSense from Inforsense into the GeneChip-compatible Applications Program,” said Steve Lincoln, Vice-President of Informatics at Affymetrix. “GenSense is deeply integrated with the Affymetrix microarray platform at both the microarray data and annotations levels, enabling researchers to focus more of their efforts on the results and their scientific interpretation."
“Our relationship with Affymetrix enhances our joint customers’ ability to build ad-hoc analysis and data workflows for streamlining Genome Wide Association Studies,” said Jonathan Sheldon, CSO, InforSense. “We are very pleased to have Affymetrix as part of our Open Workflow Partner Network to continue expanding the capabilities available through the InforSense platform.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.